BioAge Labs

BioAge is pleased to announce the initiation of the STRIDES Phase 2 clinical trial evaluating azelaprag, an oral exercise mimetic, for the treatment of obesity. Azelaprag has the potential to increase weight loss while improving body composition when combined with an incretin drug. The STRIDES trial, conducted in collaboration with Lilly and Lilly Chorus, will evaluate the combination of azelaprag with tirzepatide, with a primary endpoint of weight loss at 24 weeks. This trial represents an important milestone in our mission to develop novel therapies for metabolic diseases by targeting the biology of aging. https://lnkd.in/g_U9C3SN Keep reading for more details about this exciting development: • Enhancing the efficacy of incretin therapy with an oral exercise mimetic:  STRIDES aims to show that azelaprag can significantly increase weight loss in patients taking incretin drugs. Azelaprag is an oral, small molecule agonist of the apelin receptor designed to mimic key biological effects of exercise. Beyond weight loss, the STRIDES trial will evaluate whether azelaprag can improve body composition and measures of metabolic health and function. • Synergistic approach to weight management, analogous to diet and exercise:  By combining azelaprag, an exercise mimetic, with tirzepatide, which reduces food intake, we aim to create a pharmacological parallel to the diet+exercise foundation of traditional obesity interventions. • Enabling all-oral regimens for healthy weight loss:  As an orally available, well tolerated small molecule, azelaprag aligns with patient preferences (77% of patients strongly prefer the convenience of oral meds over injectables). In the future, azelaprag has the potential to be combined with oral incretins currently in development into all-oral regimens for healthy weight loss. • Reaching a key patient demographic, older adults:  STRIDES will focus on individuals 55 and older, who represent 35-40% of obese adults in the US, and can be especially vulnerable to the health impacts of obesity. This trial represents a key step in our broader strategy to target the biology of aging to treat metabolic diseases.

Tonight at the Aging Research & Drug Discovery Meeting , BioAge CBO & Head of Brain Aging Peng Leong joined a panel of luminaries to discuss the dense connections between early-stage development in longevity biotech and the broader pharma sector. Their wide-ranging conversation encompassed the concepts at the very foundation of longevity biotech, the challenges of translating geroscience into the clinic, and how they envision the future of drug discovery and development at the intersection of aging biology and disease. • What are the optimal indications for clinical trials? • How do earlier-stage biotechs get to know potential pharma partners? • What is pharma looking for in the biotech startups they partner with? • Where are the opportunities to be grasped - and the pitfalls to be avoided? Many thanks to amazing moderator Michael Ringel of Boston Consulting Group (BCG) for his thoughtful and incisive questions, and to the stellar panelists - David Glass (Regeneron), Johan Luthman (Lundbeck), Jonathan Wilson (Eli Lilly and Company), and Alex Zhavoronkov (Insilico Medicine) - for a fascinating discussion!

Action shot! Naisha S., BioAge's VP-Data Science, giving her talk entitled "Targeting aging biology: exercise induced pathways for the treatment of metabolic disease" on the main stage at the Aging Research & Drug Discovery Meeting in Copenhagen.

At the Aging Research & Drug Discovery Meeting in Copenhagen today, our VP of Data Science Naisha S. gave a talk on drug target discovery for metabolic disease at the intersection of exercise and aging. Her presentation showcased how how BioAge analyzes human longevity data to identify exercise-induced pathways, underpinning our mission to develop therapies for metabolic diseases.

We are delighted to welcome Sangita Ghosh, PhD as BioAge's new Senior Vice President of Chemistry, Manufacturing, and Controls (CMC). With over two decades of experience in pharmaceutical development and a track record of bringing multiple drugs to market, Dr. Ghosh will be instrumental as we progress our lead candidate, azelaprag, through clinical trials. Great to have you on the team, Sangita!

BioAge is proud to sponsor the 2024 Aging Research & Drug Discovery Meeting , the 11th in a series that has grown into the essential annual conference for the longevity biotech sector and our collaborators in academic and pharma. Kicking off today in Copenhagen 🇩🇰 — looking forward to seeing all of our friends & colleagues who will be attending!

BioAge is pleased to announce the appointment of Jean Pierre Garnier, PhD, as Chair of our Board of Directors. Dr. Garnier, who served as CEO of GSK and has guided multiple biopharma companies through critical growth phases, brings unparalleled industry leadership to our Board. His expertise will be instrumental as we advance our lead product candidate azelaprag through Phase 2 trials for obesity and progress our pipeline of metabolic aging therapies. We also extend our deep gratitude to outgoing Chair James H., MD, PhD, for his leadership during a pivotal time for BioAge, and we're glad that he will continue to contribute his insights as a Board Director. https://lnkd.in/gJ7gQ5i4

Thanks to all who joined us for our fourth Boston longevity biotech networking event, where BioAge and more than a hundred of our friends enjoyed fascinating talks, breathtaking views of the Boston waterfront, and great conversations. Deep gratitude to our speakers Anne-Ulrike Trendelenburg, Executive Director of Novartis DARe in Cambridge, and Omar Abudayyeh and Jonathan Gootenberg from Harvard Medical School; our co-sponsor Hevolution Foundation; and our gracious hosts at Boston Consulting Group (BCG) (thank you Michael Ringel for inviting us, and to your team for helping to make it happen!). We love organizing this series, and as always, we're already looking forward to next time!

The BioAge podcast, Translating Aging, features the people & companies advancing the science of human longevity and discovering drugs to extend healthspan. Our newest episode just dropped!

Starts today at 11 AM PT/ 2 PM ET! Still time to register...